custirsen sodium
Sponsors
NCIC Clinical Trials Group, Achieve Life Sciences
Conditions
Bladder CancerBreast CancerCastrate-Resistant Prostate CancerHormone Refractory Prostate CancerKidney CancerLung CancerNon-small Cell Lung CancerOvarian Cancer
Phase 1
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
CompletedNCT00054106
Start: 2002-12-10End: 2008-09-22Updated: 2023-08-04
A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
CompletedNCT00138658
Start: 2004-11-30End: 2010-03-31Updated: 2012-02-06
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
CompletedNCT00471432
Start: 2003-04-04End: 2009-12-21Updated: 2023-08-04
Phase 2
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
CompletedNCT00258388
Start: 2005-09-28End: 2011-01-18Updated: 2023-08-04
OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
CompletedNCT00258375
Start: 2005-10-21End: 2008-09-22Updated: 2023-08-04
Phase 3
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
TerminatedNCT01083615
Start: 2010-03-31End: 2013-03-31Updated: 2016-10-12
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
CompletedNCT01578655
Start: 2012-08-31End: 2016-07-31Updated: 2016-10-12